From the academy
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

https://doi.org/10.1016/j.jaad.2018.11.057Get rights and content

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.

Key words

biologic agents
clinical guidelines for psoriasis
dermatology
guidelines
monoclonal antibodies
psoriasis
skin disease

Abbreviations used

AAD
American Academy of Dermatology
BSA
body surface area
FDA
Food and Drug Administration
HAART
highly active antiretroviral therapy
IBD
inflammatory bowel disease
IL
interleukin
m-PPPASI
Modified Palmoplantar Psoriasis Area Severity Index
NAPSI
Nail Psoriasis Severity Index
NB-UVB
narrowband ultraviolet B
NPF
National Psoriasis Foundation
PASI
Psoriasis Area Severity Index
PASI 75
75% improvement in the Psoriasis Area Severity Index
PASI 90
90% improvement in the Psoriasis Area Severity Index
PASI 100
100% improvement in the Psoriasis Area Severity Index
PPPASI
Palmoplantar Psoriasis Area Severity Index
PsA
psoriatic arthritis
PSSI
Psoriasis Scalp Severity Index
QOL
quality of life
RCT
randomized controlled trial
SCC
squamous cell carcinoma
WG
work group

Cited by (0)

Funding sources: None.

American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The American Academy of Dermatology conflict of interest policy summary may be viewed at www.aad.org. The conflicts of interest of the individual working group members are listed in the text of this guideline.

Reprints not available from the authors.

View Abstract